Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2010 - 2026)
Rockwell Medical's (RMTI) quarterly Depreciation & Amortization (CF) came in at $511000.0 in Q1 2026, down 5.19% YoY from $539000.0 in Q1 2025, and down 6.41% on a QoQ basis from $546000.0 in Q4 2025.
Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Rockwell Medical (RMTI) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $511000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.19% year-over-year to $511000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.46% YoY) and the FY2025 annual result came in at $2.2 million, up 0.55% from the prior year.
- Depreciation & Amortization (CF) fell to $511000.0 in Q1 2026, from $546000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $564000.0 in Q3 2023 to a low of $138000.0 in Q1 2022.
- A 5-year average of $406058.8 and a median of $543000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 31.68% — and 2023, when it surged 294.41%.
- Tracing RMTI's Depreciation & Amortization (CF) over 5 years: stood at $154000.0 in 2022, then soared by 257.14% to $550000.0 in 2023, then retreated by 1.27% to $543000.0 in 2024, then grew by 0.55% to $546000.0 in 2025, then decreased by 6.41% to $511000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $511000.0 (Q1 2026), $546000.0 (Q4 2025), and $544000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Rockwell Medical | 29.81 Mn | 5.01 Mn | 3.24 Mn | 492,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 492,000.00 |
| Jun 30, 2026 | 492,000.00 |
| Mar 31, 2026 | 511,000.00 |
| Mar 31, 2026 | 511,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Mar 31, 2025 | 539,000.00 |
| Mar 31, 2025 | 539,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 545,000.00 |
| Mar 31, 2024 | 545,000.00 |